The advantage of the treatment of erectile dysfunction with sildenafil in patients in the late ontogenesis

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


The aim of the study was to evaluate the benefits and safety of sildenafil in the average patient, elderly with a high degree of comorbidity. This study included patients who applied to the advisory diagnostic center of the Military Medical Academy, they were asked to fill questionnaire MIEF-5 before and after treatment. Total were question questionaired 310 patients in middle age (45-59 years), 90 in the elderly (60-74) and 24 people in old (> 74l). 287 patients were treated by sildenofil. Sildenafil is indicated for patients with erectile dysfunction in elderly and senile patients with comorbidities. If you are using sildenafil, patients have the opportunity not to stop taking essential medicines or to receive if necessary the preparation of the nitrate groups within a short period of time.

Full Text

Restricted Access

About the authors

Vladimir I Didenko

Military Medical Academy named after S.M. Kirov

urologist, Consultative and Diagnostic Centre


  1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Intern. 1999;84(1):50-56. doi: 10.1046/j.1464-410x.1999.00142.x.
  2. Saigal CS, Wessells H, Pace J, et al. Predictors and prevalence of erectile dysfunctiob in a racially diverse population. Arch Intern Med. 2006;166(2):207-212. doi: 10.1001/archinte.166.2.207.
  3. Korneyev IA, Alexeeva TA, Al-Shukri SH, et al. Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study. Int J Impot Res. 2016; 28(2):74-79. doi: 10.1038/ijir.2016.8.
  4. Дильман В.М. Четыре модели медицины. - Л.: Медицина, Ленингр. отд-ние, 1987. - 287 с. [Dil’man VM. Chetyre modeli meditsiny. Leningrad: Meditsina; 1987. 287 p. (In Russ.)]
  5. Cheitlin MD, Hutter AMJr, Brindis RG, et al. Technology and Practice Executive Committee. Use of sildenafil (Viagra) in patients with cardiovascular disease [published correction appears in Circulation. 1999;100:2389]. Circulation. 1999;99:168-177.
  6. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378-1385. doi: 10.1016/j.jacc.2011.06.024.
  7. Guay AT. Optimizing response to phosphodiesterase therapy: impact of risk-factor management. J Androl. 2003;24(6): S59-S62. doi: 10.1002/j.1939-4640.2003.tb02748.x.
  8. Корнеев И.А. Эректильная дисфункция: особенности диагностики и медикаментозного лечения мужчин с сопутствующими заболеваниями // Consilium medicum. - 2015. - Т. 17. - № 7. - С. 32-36. [Korneev IA. Erektil’naya disfunktsiya: osobennosti diagnostiki i medikamentoznogo lecheniya muzhchin s soputstvuyushchimi zabolevaniyami. Consilium medicum. 2015;17(7):32-36. (In Russ.)]



Abstract - 508

PDF (Russian) - 347


Article Metrics

Metrics Loading ...



Copyright (c) 2016 Didenko V.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies